Delays to Research and Development, Manufacturing, and Logistics Caused by Infectious Disease Outbreaks
First written in FY2023. 1 of 3 entries say "Restated". Latest entry: FY2025.
K Pharma moved to the "Worse" side of this theme in 2026, 6 years after the typical company in this theme (2020).
The whole theme swung hardest in 2020: 24 of 39 companies on the "Worse" side.
2 other companies' latest entry also says "Worsened".
- FY2025WorsenedAnnual report
「If a major natural disaster or infectious disease outbreak occurs in areas surrounding our business sites, various business activities may be constrained, causing delays in research and development of our pharmaceuticals and regenerative medicine products and in establishing subsequent manufacturing, logistics and sales systems.」
In addition to infectious disease outbreaks, the company explicitly identifies major natural disasters as factors that may constrain business activities. - FY2024RestatedAnnual report
「If an infectious disease outbreak constrains our various business activities, delays may arise in research and development of our pharmaceuticals and regenerative medicine products and in establishing subsequent manufacturing, logistics and sales systems.」
The company reiterates the risk of delays in research and development, manufacturing, logistics and establishment of sales systems caused by infectious disease outbreaks. - FY2023First statedAnnual report
「If an infectious disease outbreak constrains our various business activities, delays may arise in research and development of our pharmaceuticals and regenerative medicine products and in establishing subsequent manufacturing, logistics and sales systems.」
The company indicates that infectious disease outbreaks may delay research and development, manufacturing, logistics and establishment of sales systems.